MedTrace Logo

LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases

NCT06837961 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2025-11-18

No results posted yet for this study

Summary

The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing clinical symptoms of upper respiratory infectious diseases in healthy adults. Researchers will compare LC-Plasma to placebo, participants will take a tablet containing LC-Plasma or placebo daily for 4 weeks.

Conditions

  • Healthy Volunteer
  • Immune Response

Interventions

DIETARY_SUPPLEMENT

LC-Plasma

1 tablet containing 50mg LC-Plasma is taken daily for 4 weeks

OTHER

Placebo

1 tablet containing 50mg MCC is taken daily for 4 weeks

Sponsors & Collaborators

  • Kirin Holdings Company, Limited

    collaborator INDUSTRY

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Yusuke Ushida · Kirin Holdings Company, Limited

  • Osamu Kanauchi · Kirin Holdings Company, Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-29
Primary Completion
2025-11-03
Completion
2025-11-03

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06837961 on ClinicalTrials.gov